2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Checkpoint Inhibitor, Workforce, Clinical Practice (Health Services and Quality), Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3581 Efficacy of PD-1 maintenance after autologous stem cell transplantation in relapsed/refractory classic Hodgkin lymphoma: Long-term follow-up of two phase II trials and a propensity-score matching analysis

Reid W Merryman, MD, Robert Redd, MS2, Lu Chen, PhD3, Ayo Samuel Falade, MD, MBA4, Harsh Rohit Shah, DO5, Kelsey Baron, MD6, Sanjal Himanshu Desai, MBBS7, Nivetha Ganesan, MPH8, Tiffany Chang9, Robert Stuver, MD10, Matthew Mei I, MD11, Yi-Bin Chen, MD,MS12, Zachariah Defilipp, MD13, Robin Joyce, MD14, Jon E Arnason, MD15, Leona Holmberg, MD, PhD16, Tatyana Feldman, MD17, Patrick Johnston, MD, PhD18, Yago Nieto, MD, Ph.D19, Alison Moskowitz, MD20, Philippe Armand, MD21, Alex Francisco Herrera, MD22, Swetha Thiruvengadam, MD23
1 Dana-Farber Cancer Institute, Boston, United States
2 Dana-Farber Cancer Institute, Boston, United States
3 City of Hope National Medical Center, Duarte, United States
4 Mayo Clinic, Rochester, United States
5 The University of Utah, Salt Lake City, United States
6 The University of Utah, Salt Lake City, United States
7 University of Minnesota, Minneapolis, United States
8 Memorial Sloan Kettering Cancer Center, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, United States
11 City of Hope National Medical Center, Duarte, United States
12 Massachusetts General Hospital, Boston, United States
13 Massachusetts General Hospital, Boston, United States
14 Beth Israel Deaconess Medical Center, Boston, United States
15 Beth Israel Deaconess Medical Center, Boston, United States
16 University of Washington and Clinical Division, Fred Hutchinson Cancer Center, Seattle, United States
17 Hackensack University John Theurer Cancer Center, Hackensack, United States
18 Mayo Clinic, Rochester, United States
19 University of Texas MD Anderson Cancer Center, Houston, United States
20 Memorial Sloan Kettering Cancer Center, New York, United States
21 Dana-Farber Cancer Institute, Boston, United States
22 City of Hope National Medical Center, Duarte, United States
23 City of Hope National Medical Center, Duarte, United States

Background: Outcomes for patients (pts) with relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) have improved due to more effective salvage therapies and post-autologous stem cell transplantation (ASCT) maintenance therapy with brentuximab vedotin (BV). Two trials have reported outcomes of post-ASCT maintenance strategies that incorporate a PD-1 monoclonal antibody (mAb) – a phase II trial of pembrolizumab (pembro) and a phase II trial of BV and nivolumab (nivo). Both trials met their primary endpoint of improvement in 18-month progression-free survival (PFS) compared to historical controls. Here, we report long-term outcomes from the two trials. To better understand the potential benefit of PD-1-based maintenance therapy, we also performed a propensity-score matching (PSM) analysis including pts from these trials and matched pts from a multicenter ASCT database.


Methods: The pembro trial (NCT02362997) enrolled 30 pts (4/2015-3/2017) and the BV+nivo trial (NCT03057795) enrolled 59 pts (5/2017-7/2019). Eligibility criteria for the trials were generally similar and included age≥18 and diagnosis of R/R cHL with at least a partial response (pembro trial) or at least stable disease (BV+nivo trial) on pre-ASCT positron emission tomography (PET). Study therapy consisted of pembro (200 mg) every 3 weeks for up to 8 cycles, starting within 60 days of ASCT (pembro trial) or BV (1.8mg/kg) and nivo (3mg/kg) for up to 8 cycles, starting within 75 days of ASCT (BV+nivo trial). Trial pts were matched with pts from a multicenter ASCT database (n=1800). Propensity scores were derived based on covariates of age, year (yr) of ASCT, relapse within 12 months or primary refractory disease, B symptoms at relapse, extranodal (EN) sites at relapse, complete metabolic response (CMR) on pre-ASCT PET scan, number of salvage regimens, receipt of peri-ASCT radiation (XRT), receipt of pre-ASCT PD-1, receipt of pre-ASCT BV, and receipt of post-ASCT BV maintenance. Pts were matched 2:1 without replacement using the nearest neighbor method (caliper 0.2 standard deviations of the logit propensity score) to minimize observed differences in covariates. The analysis was restricted to 1605/1889 pts with complete data on all matching covariates.


Results: Among 89 trial pts, median age was 31 (range 18-72) (BV+nivo 29 [18-72]); pembro 31 [20-69]). 75 pts (84%) had refractory disease or relapsed within 1 yr (BV+Nivo 90%; pembro 73%), 16 (18%) had B symptoms at relapse (BV+Nivo 24%; pembro 7%), and 31 (35%) had EN sites at relapse (BV+Nivo 39%; pembro 27%). Pts received a median of 1 (range 1–5) salvage regimen (BV+Nivo 1 [1–5]; pembro 1 [1–3]), including BV for 45 pts (51%) (BV+Nivo 49%; pembro 53%) and a PD-1 mAb for 30 pts (34%) (BV+Nivo 42%; pembro 17%). 71 pts (80%) were in a CMR before ASCT (BV+Nivo 81%; pembro 77%); and 4 pts (4%) received peri-ASCT XRT (BV+Nivo 2%; pembro 10%).

With a median follow-up (f/u) of 9.3 yrs for the pembro trial, 9yr PFS and overall survival (OS) are 86% (95CI 74-100) and 96% (95CI 89-100), respectively. With a median f/u of 6.2 yrs for the BV+nivo trial, 6yr PFS and OS are 93% (95CI 87-100) and 98% (95CI 95-100), respectively.

Of 89 trial pts, 63 (71%) were matched to a control pt; the remaining 26 pts could not be matched due to lack of adequate overlap in propensity scores with the control cohort and were excluded from the matched analysis. After matching, all key variables were similar between the trial (n=63) and control (n=109) groups, except yr of ASCT which was later in the control group (median 2018 vs 2017, p=0.01). The median f/u for all pts in the PSM analysis was 5.0 yrs (3.1 yrs controls, 7.1 yrs trial pts). PFS was significantly improved for trial pts (3yr PFS 92% vs 71%, p=0.006). Similar trends were seen for subsets of pts who received BV (3yr 95% vs 80%, p=0.069) or a PD-1 mAb (3yr 94% vs 84%, p=0.18) before ASCT. There was no difference in OS between the trial and matched cohorts (3yr OS 98% vs 94%, p=0.12).

Conclusion: With extended f/u, post-ASCT maintenance therapy with a PD-1 mAb, in the form of either pembro or BV+nivo, is associated with excellent outcomes. When compared to a matched cohort, we observed a significant improvement in PFS among pts receiving PD-1 maintenance. This trend was observed in all pt subgroups, but the absolute benefit of PD-1 maintenance may be attenuated among pts receiving PD-1 before ASCT. Additional investigation of post-ASCT PD-1 maintenance is warranted.

Reid W Merryman, MD: Abbvie - Honoraria; Genmab - Honoraria; Genentech/Roche - Research Funding; Merck - Research Funding; Genmab - Research Funding; Bristol-Myers Squibb - Research Funding; KITE - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)